DUBLIN, Mar. 03, 2015 /PRNewswire/ --Research and
Markets
(http://www.researchandmarkets.com/research/gxqhg9/gene_therapy)
has announced the addition of Jain PharmaBiotech's new report "Gene
Therapy - Technologies, Markets and Companies" to their
offering.
Gene therapy technologies are described in detail including
viral vectors, nonviral vectors and cell therapy with genetically
modified vectors. Gene therapy is an excellent method of drug
delivery and various routes of administration as well as targeted
gene therapy are described. There is an introduction to
technologies for gene suppression as well as molecular diagnostics
to detect and monitor gene expression.
Clinical applications of gene therapy are extensive and cover most
systems and their disorders. Full chapters are devoted to genetic
syndromes, cancer, cardiovascular diseases, neurological disorders
and viral infections with emphasis on AIDS. Applications of gene
therapy in veterinary medicine, particularly for treating cats and
dogs, are included.
Research and development is in progress in both the academic and
the industrial sectors. The National Institutes of Health (NIH) of
the US is playing an important part. As of 2014, over 2050 clinical
trials have been completed, are ongoing or have been approved
worldwide.A breakdown of these trials is shown according to the
geographical areas and applications.
Since the death of Jesse Gelsinger
in the US following a gene therapy treatment, the FDA has further
tightened the regulatory control on gene therapy. A further setback
was the reports of leukemia following use of retroviral vectors in
successful gene therapy for adenosine deaminase deficiency. Several
clinical trials were put on hold and many have resumed now. The
report also discusses the adverse effects of various vectors,
safety regulations and ethical aspects of gene therapy including
germline gene therapy.
The markets for gene therapy are difficult to estimate as there is
only one approved gene therapy product and it is marketed in
China since 2004. Gene therapy
markets are estimated for the years 2014-2024. The estimates are
based on epidemiology of diseases to be treated with gene therapy,
the portion of those who will be eligible for these treatments,
competing technologies and the technical developments anticipated
in the next decades. In spite of some setbacks, the future for gene
therapy is bright.The markets for DNA vaccines are calculated
separately as only genetically modified vaccines and those using
viral vectors are included in the gene therapy markets
The voluminous literature on gene therapy was reviewed and selected
750 references are appended in the bibliography.The references are
constantly updated. The text is supplemented with 75 tables and 15
figures.
Profiles of 181 companies involved in developing gene therapy are
presented along with 223 collaborations. There were only 44
companies involved in this area in 1995. In spite of some failures
and mergers, the number of companies has increased more than 4-fold
within a decade.
Key Topics Covered:
Executive Summary
1. Introduction
2. Gene Therapy Technologies
3. Clinical Applications of Gene Therapy
4. Gene Therapy of Genetic Disorders
5. Gene Therapy of Cancer
6. Gene Therapy of Neurological Disorders
7. Gene Therapy of Cardiovascular Disorders
8. Gene therapy of viral infections
9. Research, Development and Future of Gene Therapy
11. Markets for Gene Therapy
12. References
13. Companies involved in Gene Therapy
For more information visit
http://www.researchandmarkets.com/research/gxqhg9/gene_therapy
Source: Jain PharmaBiotech
Media Contact: Laura Wood ,
+353-1-481-1716, press@researchandmarkets.net
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/gene-therapy-market-report-2014-2024---technologies-markets-and-companies-300044440.html
SOURCE Research and Markets